Shots:

• The company highlighted 2 posters of the P-III trials evaluating SB15 (developed by Samsung Bioepis) & MYL-1701P (developed by Momenta & Viatris) vs Eylea in a ratio (1:1) in 449 treatment-naive nAMD patients & 355 patients
• In a 32wk. analysis of SB15, the 1EPs were found to be equivalent with no new safety signals, and incidence & severity of TEAEs b/w 2 products were similar ~32wk. while immunogenicity & PK profiles were also similar
• The (INSIGHT) Study on MYL-1701P showed the therapeutic equivalence b/w drugs, TEAEs were comparable for the biosimilar & reference product with no differences regarding antidrug Abs, patients who had gains and losses in visual acuity were similar b/w the treatment arms & was safe & well tolerated  

Ref: Biosimilars | Image: Samsung Bioepis